Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.30
- Piotroski Score 6.00
- Grade Overweight
- Symbol (JNJ)
- Company Johnson & Johnson
- Price $162.05
- Changes Percentage (0.4%)
- Change $0.65
- Day Low $160.68
- Day High $162.18
- Year High $168.85
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
- Last Earnings 07/17/2024
- Ex-Dividend for 5/16 Dividend 08/27/2024
- Dividend Payable 09/10/2024
- Today N/A
- Next Earnings (Estimated) 10/14/2024
- Fiscal Year End N/A
- Average Stock Price Target $175.00
- High Stock Price Target $205.00
- Low Stock Price Target $150.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $6.73
- Trailing P/E Ratio 21.85
- Forward P/E Ratio 21.85
- P/E Growth 21.85
- Net Income $35.15 B
Income Statement
Quarterly
Annual
Latest News of JNJ
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Johnson & Johnson (JNJ): Hedge Funds Bet Big on Healthcare Giant Amid 4.3% Q2 Revenue Increase
An analysis of top healthcare stocks favored by hedge funds includes Johnson & Johnson (NYSE:JNJ), a leading multinational healthcare corporation. JNJ's commitment to innovation and health equity driv...
By Yahoo! Finance | 22 hours ago -
Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment
Johnson & Johnson shared new data from two early-stage studies on Talvey combination treatment for multiple myeloma. Results show promising overall response rates and progression-free survival in pati...
By Yahoo! Finance | 3 days ago -
Is Johnson & Johnson (JNJ) the Best Stock To Buy Right Now According To Billionaire Cliff Asness?
Billionaire Cliff Asness's investment strategy focuses on quality metrics like profitability, growth, and safety in selecting stocks. AQR Capital Management's strong performance in 2023 and Q1 2024 wa...
By Yahoo! Finance | 4 days ago
